T-cell-engager cytokine-release network
Reference paper ↗A cytokine-network QSP model coupling drug exposure to resting, activated, cytotoxic, and exhausted T cells and to IL-6, IL-10, IL-1beta, IFN-gamma, and TNF-alpha dynamics.
- Therapeutic
- Blinatumomab and comparator T-cell agonists
- Modality
- Bispecific antibody / T-cell engager
- Target
- CD19, CD3, CD28, IL-6R / CD126
- Disease
- Cytokine-release syndrome
- Model type
- QSP, TCE/BsAb
Complete model workspace
Checking workspace access…
- Parameters
- 33
- States
- 11
- Equations
- 11
- Derived outputs
- 46
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
blinatumomab 28 ug/day continuous infusion through day 28
How do drug exposure and immune feedback shape T-cell activation and the timing and magnitude of cytokine release? Explore this biological starting configuration through T-cell agonist concentration, Activated T cells, IL-6, IFN-gamma, TNF-alpha.
Starting result
This result reflects the starting settings. Run your changes to update it.
Result preview could not load
The generated result could not be loaded. The inputs remain available below.
Starting configuration
Time: 0–672 hour; step 2
| Input | Default | Available range |
|---|---|---|
| Systemic clearance | 2.1 L/hour | 1.05–3.15 L/hour |
| T-cell activation EC50 | 1 nM | 0.5–1.5 nM |
| Maximum activated T-cell concentration | 5,000 cell/uL | 2,500–7,500 cell/uL |
| Macrophage activation EC50 | 48.6 pg/mL | 24.3–72.9 pg/mL |
| IC50 IL-10 | 50 pg/mL | 25–75 pg/mL |
Expected readouts
Drug concentration (nM) · Activated t (cell/uL) · Il 6 (pg/mL) · Ifn gamma (pg/mL) · Tnf alpha (pg/mL)
Adjustable model parameters
This public explorer exposes 5 curated parameters. Sign in to edit all 33 declared model parameters.
More key parameters (1)
How the model represents the biology
A cytokine-network QSP model coupling drug exposure to resting, activated, cytotoxic, and exhausted T cells and to IL-6, IL-10, IL-1beta, IFN-gamma, and TNF-alpha dynamics.
Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.
Model scope: CD19/CD3/CD28 and IL-6R binding, tissue compartments, dynamic macrophage-cell states, and tocilizumab PK or occupancy are not represented.
Modeled relationships (9)
- T-cell agonist input → Agonist exposure: input (flow)
- Agonist exposure → T-cell program: activation (modulation)
- T-cell program → Pro-inflammatory cytokines: IFN-γ / TNF-α (production)
- Pro-inflammatory cytokines → Macrophage signal: macrophage drive (modulation)
- Macrophage signal → Pro-inflammatory cytokines: IL-6 / IL-1β (production)
- Macrophage signal → IL-10 feedback: IL-10 (production)
- IL-10 feedback → Pro-inflammatory cytokines: suppression (modulation)
- Pro-inflammatory cytokines → Optional IL-6 feedback: IL-6 feedback (modulation)
- Optional IL-6 feedback → Pro-inflammatory cytokines: switchable (modulation)
Modeled relationships: T-cell agonist input to Agonist exposure: input (flow); Agonist exposure to T-cell program: activation (modulation); T-cell program to Pro-inflammatory cytokines: IFN-γ / TNF-α (production); Pro-inflammatory cytokines to Macrophage signal: macrophage drive (modulation); Macrophage signal to Pro-inflammatory cytokines: IL-6 / IL-1β (production); Macrophage signal to IL-10 feedback: IL-10 (production); IL-10 feedback to Pro-inflammatory cytokines: suppression (modulation); Pro-inflammatory cytokines to Optional IL-6 feedback: IL-6 feedback (modulation); Optional IL-6 feedback to Pro-inflammatory cytokines: switchable (modulation).
Primary readouts: Agonist concentration; Activated T cells; IL-6; IFN-γ; TNF-α.
Related models
Research use only — not for patient-specific prediction or dosing advice.